

The evolution of biosimilar insulins: A review of current formulations and market impact

Saloni Bhatti¹, Mona Piplani²

¹Department of Pharmaceutics, School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India

²Department of Pharmaceutics, Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India

Correspondence:

Dr. Mona Piplani, Maharaj Agrasen School of Pharmacy, Maharaja Agrasen University Kalujhanda, Baddi, Solan, Himachal Pradesh, India.
E-mail: salonithakur.5@gmail.com

How to cite this article:

Bhatti S. The evolution of biosimilar insulins: A review of current formulations and market impact. *Innov Pharm Pharmacother* 2023;11(4):58-61.

Source of Support: Nil.

Conflicts of Interest: None declared.

Date of Submission: 15-10-2023

Date of Revision: 25-11-2023

Date of Acceptance: 05-12-2023

ABSTRACT

Biosimilar insulins represent a significant advancement in the management of diabetes, addressing the critical need for affordable insulin options. Biosimilars are highly similar to their reference biologic products, maintaining equivalent quality, safety, and efficacy. The rising costs of branded insulin have created access challenges, especially in low- and middle-income countries. The introduction of biosimilar insulins, such as Basaglar and Semglee, offers promising solutions by increasing competition in the insulin market, potentially reducing costs. This review explores the evolution of biosimilar insulins, regulatory pathways, and the scientific rigor behind their development, including pharmacokinetic, pharmacodynamic, and clinical trial assessments. While biosimilars must demonstrate comparability to their reference products, they offer cost savings and improved access without compromising therapeutic efficacy. However, regulatory and market challenges remain, particularly regarding pricing models, which will shape the long-term impact of biosimilar insulins on healthcare systems and diabetes management.

Keywords: Basaglar, biosimilar insulins, cost-effectiveness, diabetes management, insulin therapy, pharmacodynamics, pharmacokinetics, regulatory approval, Semglee

Introduction

Definition of biosimilars

Biosimilars are biologic medical products that are highly similar to an original product manufactured by a different company. Unlike generic drugs, which are exact copies of their brand name counterparts, biosimilars cannot be made as precise replicas due to the inherent complexity and natural variability of biologics. However, biosimilars must demonstrate that they are highly similar to the reference product in terms of quality, safety, and efficacy.^[1]

Importance of insulin in diabetes management

Insulin is a critical hormone for the management of diabetes, a chronic condition characterized by the body's inability to regulate blood sugar levels effectively. Insulin therapy is essential for maintaining glycemic control and preventing or delaying the onset of diabetes-related complications. The availability of safe and effective insulin products has significantly improved the lives of millions of people with diabetes worldwide.^[1]

Emergence of biosimilar insulins

The high cost of branded insulin products has led to concerns about accessibility and affordability, particularly in low- and middle-income countries. The introduction of biosimilar insulins aims to increase competition in the insulin market, potentially driving down prices and expanding access to this essential medication. As more biosimilar insulins become available, it is crucial to evaluate their potential impact on diabetes management and the overall healthcare system.^[2]

Access this article online

Website: <https://innovationaljournals.com/index.php/ip> **e-ISSN:** 2348-7275

DOI: 10.31690/ipplanet.2023.v011i04.016

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution NonCommercial Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

This review article will explore the current landscape of biosimilar insulins, their regulatory approval process, and the clinical evidence supporting their use in the management of diabetes. In addition, it will discuss the potential challenges and opportunities associated with the adoption of biosimilar insulins in various healthcare settings.^[3]

Background: The Insulin Market

History of insulin development

Insulin therapy has undergone significant advancements since its discovery in 1921. Initially, insulin was extracted from the pancreas of animals, primarily cows and pigs. These animal-derived insulins were used for decades, but they posed challenges such as potential allergic reactions and the need for higher doses due to differences in amino acid sequences compared to human insulin.^[4]

In the late 1970s, the development of recombinant DNA technology enabled the production of biosynthetic human insulin using genetically modified bacteria. This breakthrough not only resolved supply and price volatility issues associated with animal-derived insulins but also paved the way for the development of insulin analogs.^[5]

Insulin analogs are modified versions of human insulin designed to have improved pharmacokinetic (PK) properties, such as faster onset of action (rapid-acting analogs) or longer duration of action (long-acting analogs). These analogs offer more precise blood glucose control and improved flexibility in dosing compared to regular human insulin.

Challenges in insulin access

Despite the advancements in insulin development, access to affordable insulin remains a significant challenge, particularly in low- and middle-income countries. The rising costs of insulin have made it increasingly unaffordable for many patients, leading to suboptimal disease management and increased risk of complications.

To address these challenges, there is a growing demand for affordable alternatives, such as biosimilar insulins. Biosimilar insulins are highly similar versions of reference insulin products that have been approved by regulatory authorities based on a comprehensive comparability exercise demonstrating similarity in quality, safety, and efficacy.^[6]

Regulatory framework for biosimilars

The regulatory framework for the approval of biosimilar insulins varies across different countries and regions. In the United States, the Food and Drug Administration (FDA) has established a pathway for the approval of biosimilar and interchangeable biological products under the Biologics Price Competition and Innovation Act.

Similarly, the European Medicines Agency (EMA) has developed a regulatory framework for the approval of biosimilar medicinal products. The EMA's guidelines outline the requirements for demonstrating similarity in quality, safety, and efficacy between the biosimilar and the reference product.

Other regulatory authorities, such as the World Health Organization, have also developed guidelines for the evaluation of similar biotherapeutic products, including biosimilar insulins. These guidelines aim to provide a framework for ensuring the quality, safety, and efficacy of biosimilar products while promoting access to affordable alternatives.^[7]

Development of Biosimilar Insulins

Scientific and technical aspects

The development of biosimilar insulins is grounded in the principles of biotechnology, where complex biologics are produced through living organisms. Unlike traditional small-molecule drugs, biosimilars are large, intricate molecules that cannot be exact replicas of their reference products due to the variability inherent in biological systems. However, biosimilar insulins must demonstrate a high degree of structural and functional similarity to the reference insulins, which is established through rigorous analytical methods.

The process begins with the selection of the appropriate gene sequence for insulin, which is then inserted into a host organism, typically bacteria or yeast, to produce the insulin molecule. The resulting product undergoes extensive characterization to confirm that it matches the reference insulin in terms of primary structure (amino acid sequence), secondary and tertiary structures (folding patterns), and biological activity. Variability, known as microheterogeneity, may occur due to differences in manufacturing conditions, but regulatory authorities require that any differences do not result in clinically meaningful differences in safety or efficacy compared to the reference product.^[8]

Comparability studies

To confirm bio similarity, comprehensive comparability studies are conducted, which include PK and pharmacodynamic (PD) assessments, as well as clinical trials.

PK

These studies evaluate how the biosimilar insulin is absorbed, distributed, metabolized, and excreted in the body compared to the reference product. Parameters such as peak plasma concentration and time to peak concentration are measured to ensure that the biosimilar behaves similarly in the body.

PD

PD studies assess the biological effects of the biosimilar insulin, including its ability to lower blood glucose levels. This involves measuring the insulin's efficacy in various populations, including those with Type 1 and Type 2 diabetes.

Clinical trials

Clinical studies are crucial for establishing the safety and efficacy of biosimilar insulins. These trials typically involve a randomized, controlled design to compare the biosimilar with the reference insulin in terms of glycemic control, adverse effects, and immunogenicity. Regulatory agencies, such as the FDA and EMA, require robust clinical

data demonstrating that the biosimilar has no clinically meaningful differences from the reference product in these aspects.^[9]

The successful completion of these studies is essential for obtaining regulatory approval, allowing biosimilar insulins to enter the market as safe and effective alternatives to their reference counterparts. The emergence of biosimilar insulins represents a significant opportunity to improve access to insulin therapy, particularly in light of rising costs and the need for affordable diabetes management options.^[10]

Current Biosimilar Insulin Formulations

Overview of available biosimilar insulins

As of 2022, several biosimilar insulin products have been introduced to the market, providing patients with more affordable options for diabetes management. Notable examples include:

Basaglar (insulin glargine)

Approved in 2015, Basaglar is a biosimilar to Lantus, offering a long-acting insulin option for patients requiring basal insulin therapy.

Semglee (insulin glargine)

This biosimilar received FDA approval in 2021 and has been granted interchangeable status, allowing it to be substituted for Lantus without the need for a new prescription. Semglee is recognized for its potential to improve access to insulin therapy due to its lower cost compared to branded options.

These biosimilars aim to provide similar therapeutic effects as their reference products while offering cost savings for healthcare systems and patients alike.^[9]

Comparison to reference products

Biosimilar insulins are required to demonstrate a high degree of structural and functional similarity to their reference products.

Similarities

Both biosimilar and reference insulins share the same active ingredient, pharmacological effects, and indications for use. For instance, Basaglar and Lantus both provide long-acting insulin coverage, helping to manage blood glucose levels in diabetic patients.

Differences

While biosimilars may exhibit minor differences in inactive ingredients or manufacturing processes, these variations do not impact their clinical performance. Regulatory authorities require extensive comparability studies to ensure that any differences do not lead to variations in safety or efficacy. For example, Semglee and Lantus have shown comparable PK and PD profiles in clinical trials, supporting their use as interchangeable products.^[8]

Cost-effectiveness and pricing

The introduction of biosimilar insulins has the potential to significantly reduce costs in the insulin market. Studies indicate that biosimilars can be priced 1530% lower than their reference products, which can lead to substantial savings for patients and healthcare systems.

Pricing models

The pricing of biosimilar insulins is influenced by various factors, including manufacturing costs, market competition, and regulatory policies. As more biosimilars enter the market, increased competition can drive prices down further, making insulin more accessible to patients.

Cost benefits

The cost-effectiveness of biosimilar insulins can lead to improved adherence to treatment among patients who may have previously struggled to afford branded insulins. This is particularly crucial given that high insulin costs have been linked to non-adherence and poor diabetes management, which can result in more significant long-term healthcare costs due to complications.

Overall, the emergence of biosimilar insulins represents a promising development in diabetes care, addressing the critical issue of insulin affordability while maintaining therapeutic efficacy and safety.

Market Impact of Biosimilar Insulins

Market penetration and competition

The biosimilar insulin market is rapidly evolving, with an increasing number of players entering the field. As of 2022, the market share of biosimilar insulins is projected to grow significantly, driven by the expiration of patents for first-generation insulin analogs and the increasing demand for affordable diabetes therapies.^[7]

Key players in the biosimilar insulin market include

Biocon and Viartis: The developers of Semglee, which has gained traction in the market due to its interchangeable status.

Sanofi

While primarily a manufacturer of branded insulins, Sanofi is also exploring opportunities in the biosimilar space.

The competition between biosimilar manufacturers and traditional branded insulin producers is expected to intensify, leading to further price reductions and enhanced patient access to insulin therapy.

Patient access and affordability

Biosimilar insulins have the potential to significantly improve patient access to insulin, particularly for those who have faced financial barriers to treatment. By providing lower-cost alternatives, biosimilars can reduce out-of-pocket expenses for patients, making it easier for them to adhere to prescribed insulin regimens.

Research indicates that the introduction of biosimilar insulins has already begun to influence patient access positively. For example, studies have shown that patients who switch to biosimilar insulins report improved affordability and reduced financial strain, leading to better overall diabetes management.^[10]

Regulatory and Policy Challenges

Despite the promising potential of biosimilar insulins, several barriers to their adoption remain

Patent protections

Existing patents on reference insulins can delay the entry of biosimilars into the market, limiting competition and keeping prices high.

Prescriber hesitation

Some healthcare providers may be hesitant to prescribe biosimilar insulins due to concerns about their safety and efficacy compared to reference products. Education and awareness initiatives are essential to address these concerns and promote confidence in biosimilar therapies.

Regulatory hurdles

Navigating the regulatory landscape for biosimilars can be complex, with varying requirements across different countries. Streamlining these processes could facilitate faster market entry for biosimilar insulins.

Impact on global markets

The influence of biosimilar insulins extends beyond high-income countries, with significant implications for developing nations and low-income regions. In many parts of the world, access to affordable insulin remains a critical issue, and biosimilars can play a vital role in addressing this challenge.

By providing cost-effective alternatives to branded insulins, biosimilars can help improve diabetes care in resource-limited settings, ultimately reducing the burden of diabetes-related

complications and enhancing the quality of life for millions of patients globally.^[11]

Conclusion

Biosimilar insulins have the potential to transform diabetes care by providing more affordable alternatives to branded insulin products. The rigorous regulatory approval process ensures that biosimilars maintain safety, efficacy, and quality standards comparable to their reference products. As more biosimilars enter the market, pricing competition may drive down costs, increasing access to insulin for patients globally. However, challenges in market adoption and pricing strategies must be addressed to fully realize the benefits of biosimilar insulins. These products hold promise for enhancing diabetes management, reducing healthcare costs, and improving patient outcomes, particularly in underserved populations.

Reference

1. Genazzani AA, Biggio G, Caputi AP, Del Tacca M, Drago F, Fantozzi R, et al. Biosimilar drugs: Concerns and opportunities. *BioDrugs* 2007;21:351-6.
2. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. *Ann Oncol* 2008;19:411-9.
3. Sekhon BS, Saluja V. Biosimilars: An overview. *Biosimilars* 2011;2011:1-11.
4. Vecchio I, Tornali C, Bragazzi NL, Martini M. The discovery of insulin: An important milestone in the history of medicine. *Front Endocrinol (Lausanne)* 2018;9:613.
5. Quianzon CC, Cheikh I. History of insulin. *J Community Hosp Intern Med Perspect* 2012;2:25-29.
6. Gardner KE. 'The art of insulin treatment': Diabetes, insulin, and the 1920s. *J Med Humanit* 2019;40:171-80.
7. Owens DR, Monnier L, Ceriello A, Bolli GB. Insulin centennial: Milestones influencing the development of insulin preparations since 1922. *Diabetes Obes Metab* 2022;24:27-42.
8. Heinemann L, Davies M, Home P, Forst T, Vilsbøll T, Schnell O. Understanding biosimilar insulins-development, manufacturing, and clinical trials. *J Diabetes Sci Technol* 2023;17:1649-61.
9. Morris D. Biosimilar insulins: An in-depth guide. *J Diabetes Nurs* 2022;26:228.
10. Kuhlmann MK, Schmidt A. Production and manufacturing of biosimilar insulins: Implications for patients, physicians, and health care systems. *Biosimilars* 2014;4:45-58.
11. Joshi SR, Mitra S, Raj P, Suvarna VR, Athalye SN. Biosimilars and interchangeable biosimilars: Facts every prescriber, payor, and patient should know. *Insulins perspective. Expert Opin Biol Ther* 2023;23:693-704.